CHEMOTHERAPY-INDUCED ECHOCARDIOGRAPHY CHANGES IN HEPATOCELLULAR CARCINOMA PATIENTS
Introduction. Cardiovascular diseases (CVD) still remain a major health problem, occupying a leading position in the structure of morbidity and mortality. The incidence of comorbidities increases with age and when CVD is added to cancer, it becomes a major healthcare problem.
The aim. To identify earlier echocardiographic changes in myocardial dysfunction in patients with hepatocellular carcinoma without cardiovascular disease receiving targeted therapy along or in combination with transcatheter arterial embolization (TACE).
Materials and methods. In this prospective study, 73 patients undergoing targeted therapy by sorafenib and targeted therapy by sorafenib + TACE (doxorubicin) for hepatocellular carcinoma, underwent serial echocardiograms pre- and 6 months during therapy. Left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) and global longitudinal strain (GLS) of the left ventricle. The mean values of the listed echocardiography parameters were assessed both within groups over time and between groups of patients receiving different treatment protocols. The nonparametric method U Mann-Whitney (between groups) and Wilcoxon criterion (within group) were used for samples with irregular distribution. Student's t-test was used for parameters with normal distribution. Statistically significant differences were considered at p<0.05.
Results. Baseline left ventricular ejection fraction (LVEF) before targeted therapy along and targeted therapy + TACE was 61,6±4,4% vs 58,2±3,9% respectively. LVEF, LVEDV and LVESV there were no statistically significant changes in ejection fraction within 6 months from the start of therapy. However, we found a statistically significant decrease in GLS: -14,2±2,9 and -14,8±2,2, p=0,044 in both groups after 6 months targeted therapy; -20,1±2,6 and -14,2±2,9, p=0,029 in target therapy along group in dynamics after 6 months of therapy; -20,4±2,0 and -14,8±2,2, р=0,036 in target therapy + TACE group in dynamics after 6 months of therapy.
Conclusion. GLS can be used to determine preclinical myocardial systolic dysfunction in patients undergoing anticancer therapy.
Количество просмотров: 68
Категория статей:
Оригинальное исследование
Библиографическая ссылка
Kubekova S. Rib Ye. Zagorulya N. Malayev N. Biktashev D. Zhukusheva Sh. Chemotherapy-Induced Echocardiography Changes in Hepatocellular carcinoma Patients // Nauka i Zdravookhranenie [Science & Healthcare]. 2025. Vol.27 (6), pp. 47-53. doi 10.34689/SH.2025.27.6.006Похожие публикации:
COMPARATIVE EVALUATION OF BLOOD COLLECTION TUBES AND EXTRACTION METHODS FOR CIRCULATING TUMOR DNA
INFLUENCE OF SEX HORMONE-BINDING GLOBULIN (SHBG) ON THE LEVEL OF FREE TESTOSTERONE FRACTION IN OLDER OVERWEIGHT MEN
ASSESSMENT OF THE PROBABILITY OF DEVELOPING CARDIORENAL SYNDROME TYPE 2 DEPENDING ON POTENTIAL BIOMARKERS IN PEDIATRIC PATIENTS
MORPHO-GENETIC VARIABILITY IN MYOCARDIAL TISSUE AFTER SEPTAL MYECTOMY IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A FOUR-CASE SERIES STUDY
CLINICAL EFFICACY OF SELECTIVE PLASMA FILTRATION (EVACLIO) IN CARDIOVASCULAR COMPLICATIONS: A CASE SERIES FROM THE HEART CENTER KAZAKHSTAN